Supplemental Fig S10 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Key Points

• Zilovertamab vedotin demonstrates a stable MMAE plasma concentration over time in metastatic solid tumors, indicating potential therapeutic efficacy.
• The study tracked plasma concentration profiles of MMAE in participants administered Zilovertamab vedotin IV every three weeks, revealing consistent levels.
• This phase 2 study employed intravenous infusions to assess the pharmacokinetics of MMAE—a critical component in targeting cancer cells.
• The findings may pave the way for improved treatment protocols in managing metastatic solid tumors, highlighting the drug's potential.